| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Ki: 53 nM (5-HT1A)[1]
5-HT1A modulator 2 hydrochloride targets the 5-HT1A receptor, a G protein-coupled receptor involved in regulating mood, anxiety, thermoregulation, and neurotransmitter release. It binds to 5-HT1A with a Ki of 53 nM. By binding to this receptor, the compound modulates intracellular signaling pathways, including inhibition of adenylate cyclase and regulation of ion channel activity. As an analogue of 8-OH-DPAT, it may exhibit agonist or partial agonist properties depending on the experimental system. |
|---|---|
| ln Vitro |
5-HT1A modulator 2 hydrochloride (compound 3) binds to 5-HT1A with a 53 nM Ki[1].
In vitro, 5-HT1A modulator 2 hydrochloride (compound 3) binds to 5-HT1A with a Ki of 53 nM. Its defined activity profile supports its use in receptor-binding assays and functional studies. The compound's measurable binding affinity enables detailed analysis of receptor-ligand interactions and signaling dynamics. It is used to investigate serotonergic pathways with greater precision, particularly in systems where receptor selectivity is essential. |
| ln Vivo |
In vivo, 5-HT1A modulator 2 hydrochloride is used in preclinical models to explore the pharmacological modulation of 5-HT1A receptors and evaluate potential therapeutic strategies. As a modulator of 5-HT1A receptors, it may influence neuronal excitability and synaptic transmission. The compound is used in neuroscience and neuropharmacology research to study mood regulation, anxiety, and cognitive processes. However, comprehensive in vivo efficacy data from published literature are limited.
|
| Enzyme Assay |
For non-cell-based receptor binding assays, 5-HT1A modulator 2 hydrochloride can be evaluated using membrane preparations from cells expressing human 5-HT1A receptors. Radioligand binding displacement experiments are performed using a suitable radiolabeled ligand such as [3H]-8-OH-DPAT. Membrane homogenates are incubated with increasing concentrations of the test compound and a fixed concentration of the radioligand at room temperature for 60-120 minutes. Bound radioligand is separated from free by rapid filtration through glass fiber filters. Non-specific binding is determined in the presence of excess unlabeled 8-OH-DPAT. Ki values are calculated from displacement curves using nonlinear regression analysis.
|
| Cell Assay |
For in vitro cellular assays, cells expressing human 5-HT1A receptors (e.g., CHO or HEK293 cells) are cultured in appropriate media. For functional assays, the inhibition of forskolin-stimulated cAMP accumulation is measured. Cells are treated with various concentrations of 5-HT1A modulator 2 hydrochloride in the presence or absence of a 5-HT1A agonist. cAMP levels are measured using ELISA or HTRF-based detection. The compound's ability to modulate agonist-induced cAMP inhibition is assessed, and EC50 or IC50 values are calculated from dose-response curves.
|
| Animal Protocol |
For in vivo animal studies, 5-HT1A modulator 2 hydrochloride can be administered to rodents via intraperitoneal injection or oral gavage. In models of anxiety or depression, behavioral tests such as the elevated plus maze, open field test, or forced swim test are performed following compound administration. In models of cognitive function, memory and learning tests are conducted. Dosing regimens vary depending on the specific model and desired exposure levels. Blood and tissue samples may be collected for pharmacokinetic analysis.
|
| ADME/Pharmacokinetics |
5-HT1A modulator 2 hydrochloride has a molecular weight of 213.71 and a molecular formula of C11H16ClNO. It is supplied with a purity of ≥98% and is available as a 10mM solution in DMSO. The compound should be stored desiccated at -80°C. It is shipped on dry ice. The compound is for research use only and is not intended for human consumption.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 5-HT1A modulator 2 hydrochloride has not been extensively reported. As a 5-HT1A receptor modulator, potential adverse effects may include modulation of serotonergic signaling, which could affect mood, anxiety, and thermoregulation. The compound is for research use only and is not intended for human consumption. Standard toxicological evaluation would include acute and repeated-dose toxicity studies, as well as assessment of effects on the central nervous system.
|
| References | |
| Additional Infomation |
8-Hydroxy-2-(di-n-propylamino)tetrahydronaphthalene (8-OH-DPAT) is a selective 5-HT1A serotonin agonist. Derivatives of 8-OH-DPAT with larger or more massive amine substituents than the n-propyl group appear to be inactive in presynaptic biochemical assays measuring agonist-induced feedback inhibition of 5-HT synthesis, but have never been investigated in brain binding assays. This study evaluated the activity of a series of N-phenylalkyl derivatives of 8-methoxy-2-aminotetrahydronaphthalene at [3H]-8-OH-DPAT-labeled 5-HT1A sites in the rat hippocampus. All phenylalkyl derivatives showed significant affinity for these sites, and among the compounds examined, the 3-phenylpropyl 8-hydroxy analog appeared to be the best choice, with an affinity (Ki = 1.9 nM) comparable to 8-OH-DPAT (Ki = 1.2 nM). Furthermore, the oxygen-containing substituent at the 8-position of the tetrahydronaphthalene ring is not a necessary condition for good affinity, and secondary and tertiary amines exhibit the same affinity at the central 5-HT1A binding site. The 5-HT1A site exists both presynaptic and postsynaptic; therefore, the difference between the results observed in biochemical analysis and those of this binding study may be due to the different structural requirements of the two receptors. However, this possibility seems unlikely, as the affinity of several selected analogues for striatal and hippocampal binding sites differs little. Since we have now demonstrated that amine substituents larger than propyl and unsubstituted 8-positions have good tolerance to the central 5-HT1A site, future research aimed at developing new serotonergic tetrahydronaphthalene analogues need not be limited to N-propyl or 8-hydroxy derivatives of 2-aminotetrahydronaphthalene. [1]
5-HT1A modulator 2 hydrochloride (CAS 3880-76-0) is a research-grade compound that is an analogue of 8-OH-DPAT. It is a modulator of 5-HT1A with a Ki of 53 nM for binding to 5-HT1A. It is used in neuroscience and neuropharmacology research to study serotonin receptor signaling, mood regulation, anxiety, and cognitive processes. It is available for research purposes only and is not for human use. |
| Molecular Formula |
C11H16CLNO
|
|---|---|
| Molecular Weight |
213.70
|
| Exact Mass |
213.092
|
| CAS # |
3880-76-0
|
| PubChem CID |
12924837
|
| Appearance |
Off-white to gray solid powder
|
| Boiling Point |
341.2ºC at 760mmHg
|
| Flash Point |
160.2ºC
|
| LogP |
3.013
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
172
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=CC2=C1CC(CC2)N.Cl
|
| InChi Key |
GDFOHXLSNDZEHH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C11H15NO.ClH/c1-13-11-4-2-3-8-5-6-9(12)7-10(8)11;/h2-4,9H,5-7,12H2,1H3;1H
|
| Chemical Name |
8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride
|
| Synonyms |
3880-76-0; 8-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine hydrochloride; 2-amino-8-methoxy-1,2,3,4-tetrahydronaphthalene hcl; 5-HT1A modulator 2 hydrochloride; (S)-(-)-8-methoxy-2-aminotetraline hydrochloride; (R)-(+)-8-Methoxy-2-aminotetraline hydrochloride; 5-HT1A modulator 2 (hydrochloride); 8-methoxy-2-aminotetralin hydrochloride;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (467.95 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.70 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.70 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6795 mL | 23.3973 mL | 46.7946 mL | |
| 5 mM | 0.9359 mL | 4.6795 mL | 9.3589 mL | |
| 10 mM | 0.4679 mL | 2.3397 mL | 4.6795 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
